Early-stage detection
Epigenetic alterations appear long before structural disease. We intercept the earliest molecular events to catch cancer when it is most treatable.
PlasmaDtect is a biotechnology company pioneering ultra-sensitive, blood-based diagnostics — closing the clinical blindspot in early detection and Minimal Residual Disease surveillance.
Built on research lineage from world-leading institutions
Traditional tissue biopsies are invasive, costly, and slow. PlasmaDtect translates complex molecular biology into actionable, high-precision clinical insight — from a simple 10 ml blood draw.
Epigenetic alterations appear long before structural disease. We intercept the earliest molecular events to catch cancer when it is most treatable.
Highly accurate Minimal Residual Disease monitoring reveals microscopic recurrence that conventional imaging routinely misses.
Track therapeutic response as it happens, empowering oncologists to optimize treatment and proactively intercept relapse.
One simple 10 ml blood draw. A molecular testing portfolio designed for the cancers where conventional tools fall short.
Closes the critical post-surgical gap where early micro-metastases and molecular recurrence are frequently missed.
Eliminates invasive, repetitive monitoring procedures through definitive blood-based molecular surveillance.
Supports global screening with a high-throughput framework that identifies distinct epigenetic variations.
Enables early intervention and therapeutic tracking in high-risk populations where detection is notoriously difficult.
We integrate ultra-sensitive biochemical assays with advanced computational engineering — delivering an exceptionally specific cancer readout within just four days.
We collaborate with clinicians, research institutions, and healthcare innovators advancing continuous, non-invasive molecular surveillance.
Start a conversation